Marimed (MRMD) EBITDA (2011 - 2026)

Marimed (MRMD) has 16 years of EBITDA data on file, last reported at $125000.0 in Q1 2026.

• On a quarterly basis, EBITDA rose 113.74% year-over-year to $125000.0 in Q1 2026; TTM through Mar 2026 was -$1.7 million, a 2055.84% decrease from a year earlier, with the FY2025 full-year figure at -$2.8 million, down 208.09% from the prior year.
• EBITDA for Q1 2026 stood at $125000.0, up from -$4.5 million in the prior quarter.
• Over the last five years, EBITDA for MRMD reached as high as $7.0 million in Q1 2022 and fell as low as -$4.5 million in Q4 2025.
• Historically, EBITDA has averaged $2.1 million across 5 years, with a median of $2.0 million in 2024.
• Across the five-year window, EBITDA soared 156.77% in 2022 and plunged 208.24% in 2025, its largest moves.
• Year by year, EBITDA stood at $3.1 million in 2022, then decreased by 21.95% to $2.4 million in 2023, then tumbled by 160.89% to -$1.5 million in 2024, then plunged by 208.24% to -$4.5 million in 2025, then jumped by 102.76% to $125000.0 in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $125000.0 in Q1 2026, -$4.5 million in Q4 2025, and $1.6 million in Q3 2025.